Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 [Yahoo! Finance]
Neumora Therapeutics, Inc. (NMRA)
Company Research
Source: Yahoo! Finance
Outlook: Biotech Summit 2026 on February 11, Neumora executives shared additional data from the Phase 1b study of drug candidate NMRA-511. Neumora is developing NMRA-511 as a treatment for agitation in Alzheimer's disease patients. At the summit, Neumora President Josh Pinto reiterated positive results from the study and emphasized what that study was designed to show. Notably, the study was meant to estimate effect size rather than statistical significance. According to Pinto, the effect sizes were met with a favorable safety and tolerability profile. The executives believe this outcome provides a chance to advance to higher dose testing in 2026. Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 In other related news, on January 12, Leerink Partners launched coverage on Neumora Therapeutics (NASDAQ:NMRA) stock with an Outperform rating and a price target of $8. For this action, the firm pointed to Neumora's diverse portfolio, noting that several p
Show less
Read more
Impact Snapshot
Event Time:
NMRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NMRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NMRA alerts
High impacting Neumora Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NMRA
News
- Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law FirmGlobeNewswire
- Neumora Therapeutics (NMRA) had its "buy" rating reaffirmed by Guggenheim. They now have a $14.00 price target on the stock.MarketBeat
- Neumora Therapeutics (NMRA) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Neumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Highlights: Strong Financial Position ... [Yahoo! Finance]Yahoo! Finance
NMRA
Earnings
- 3/30/26 - Miss
NMRA
Sec Filings
- 4/17/26 - Form DEFA14A
- 4/17/26 - Form DEF
- 4/1/26 - Form SCHEDULE
- NMRA's page on the SEC website